|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RCAN3 |
Gene summary for RCAN3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RCAN3 | Gene ID | 11123 |
| Gene name | RCAN family member 3 | |
| Gene Alias | DSCR1L2 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A0A024RAH2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11123 | RCAN3 | LZE2T | Human | Esophagus | ESCC | 4.08e-05 | 4.78e-01 | 0.082 |
| 11123 | RCAN3 | LZE4T | Human | Esophagus | ESCC | 9.07e-09 | 1.66e-01 | 0.0811 |
| 11123 | RCAN3 | LZE7T | Human | Esophagus | ESCC | 8.02e-06 | 2.64e-01 | 0.0667 |
| 11123 | RCAN3 | LZE20T | Human | Esophagus | ESCC | 1.11e-04 | 1.50e-01 | 0.0662 |
| 11123 | RCAN3 | LZE22T | Human | Esophagus | ESCC | 2.30e-04 | 4.04e-01 | 0.068 |
| 11123 | RCAN3 | LZE24T | Human | Esophagus | ESCC | 4.64e-15 | 3.55e-01 | 0.0596 |
| 11123 | RCAN3 | P1T-E | Human | Esophagus | ESCC | 1.09e-04 | 2.59e-01 | 0.0875 |
| 11123 | RCAN3 | P2T-E | Human | Esophagus | ESCC | 9.21e-10 | 2.21e-01 | 0.1177 |
| 11123 | RCAN3 | P4T-E | Human | Esophagus | ESCC | 3.48e-09 | 2.73e-01 | 0.1323 |
| 11123 | RCAN3 | P5T-E | Human | Esophagus | ESCC | 4.21e-08 | 1.67e-01 | 0.1327 |
| 11123 | RCAN3 | P8T-E | Human | Esophagus | ESCC | 6.91e-09 | 2.06e-01 | 0.0889 |
| 11123 | RCAN3 | P9T-E | Human | Esophagus | ESCC | 4.81e-05 | 1.59e-01 | 0.1131 |
| 11123 | RCAN3 | P10T-E | Human | Esophagus | ESCC | 2.64e-37 | 7.22e-01 | 0.116 |
| 11123 | RCAN3 | P11T-E | Human | Esophagus | ESCC | 2.82e-08 | 3.53e-01 | 0.1426 |
| 11123 | RCAN3 | P12T-E | Human | Esophagus | ESCC | 5.48e-26 | 5.10e-01 | 0.1122 |
| 11123 | RCAN3 | P15T-E | Human | Esophagus | ESCC | 6.27e-22 | 5.84e-01 | 0.1149 |
| 11123 | RCAN3 | P16T-E | Human | Esophagus | ESCC | 1.54e-11 | 1.70e-01 | 0.1153 |
| 11123 | RCAN3 | P17T-E | Human | Esophagus | ESCC | 6.14e-06 | 2.78e-01 | 0.1278 |
| 11123 | RCAN3 | P19T-E | Human | Esophagus | ESCC | 1.19e-05 | 6.12e-01 | 0.1662 |
| 11123 | RCAN3 | P20T-E | Human | Esophagus | ESCC | 8.00e-23 | 5.48e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RCAN3 | SNV | Missense_Mutation | c.349N>G | p.Leu117Val | p.L117V | Q9UKA8 | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| RCAN3 | SNV | Missense_Mutation | c.610N>A | p.Glu204Lys | p.E204K | Q9UKA8 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| RCAN3 | SNV | Missense_Mutation | rs777266872 | c.325G>A | p.Glu109Lys | p.E109K | Q9UKA8 | protein_coding | tolerated(0.4) | possibly_damaging(0.479) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| RCAN3 | SNV | Missense_Mutation | novel | c.71A>G | p.Glu24Gly | p.E24G | Q9UKA8 | protein_coding | deleterious(0.03) | probably_damaging(0.986) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RCAN3 | SNV | Missense_Mutation | novel | c.671N>T | p.Pro224Leu | p.P224L | Q9UKA8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RCAN3 | SNV | Missense_Mutation | novel | c.23N>T | p.Ser8Phe | p.S8F | Q9UKA8 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.603) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RCAN3 | SNV | Missense_Mutation | rs553942744 | c.718N>A | p.Ala240Thr | p.A240T | Q9UKA8 | protein_coding | tolerated_low_confidence(0.53) | benign(0) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RCAN3 | SNV | Missense_Mutation | novel | c.211C>A | p.Leu71Ile | p.L71I | Q9UKA8 | protein_coding | deleterious(0.04) | possibly_damaging(0.817) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| RCAN3 | SNV | Missense_Mutation | novel | c.470G>T | p.Trp157Leu | p.W157L | Q9UKA8 | protein_coding | deleterious(0.03) | benign(0.033) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| RCAN3 | SNV | Missense_Mutation | rs764690503 | c.488N>T | p.Ala163Val | p.A163V | Q9UKA8 | protein_coding | deleterious(0) | possibly_damaging(0.753) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |